New diabetes combo aims for better long-term blood sugar control

NCT ID NCT06246799

Recruiting now Disease control Sponsor: The University of Texas Health Science Center at San Antonio Source: ClinicalTrials.gov ↗

First seen Mar 16, 2026 · Last updated May 24, 2026 · Updated 15 times

Summary

This study tests whether a combination of pioglitazone and tirzepatide works better than metformin plus sitagliptin for people recently diagnosed with type 2 diabetes. About 256 adults aged 18-75 who are either not on diabetes drugs or only on metformin will take part. The goal is to see which combo keeps blood sugar (HbA1c) below 6.5% for longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES (ADULT ONSET) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UT Health Science Center
RECRUITING

San Antonio, Texas, 78229, United States
University Health System Texas Diabetic Institute
RECRUITING

San Antonio, Texas, 78207, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

TYPE 2 DIABETES (ADULT ONSET)